Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Forugh Sanaee"'
Autor:
Forugh Sanaee, Tania Mysak, Laurine Sanderson, Theresa Donaldson, Mohammad Reza Vakili, Afsaneh Lavasanifar
Publikováno v:
Journal of Pharmacy & Pharmaceutical Sciences, Vol 21, Iss 1s (2018)
PURPOSE: Alberta Health Services (AHS) recommends the adoption of a new neonatal multi-trace element formulation containing zinc sulfate, copper sulfate, selenious acid and sodium iodide to be compounded internally in appropriate AHS pharmacies. The
Externí odkaz:
https://doaj.org/article/4b8f9adc51994733979f1917835a7421
Autor:
Maximilian Regenold, Lie Yun Kok, Forugh Sanaee, James C. Evans, Michael Dunne, David N. Dubins, Christine Allen, Pauric Bannigan, Lubabah Ahmed
Publikováno v:
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 168
The number of lipophilic drug candidates in pharmaceutical discovery pipelines has increased in recent years. These drugs often possess physicochemical properties that result in poor oral bioavailability, and their clinical potential may be limited w
Autor:
Afsaneh Lavasanifar, Yung-Hsing Huang, Forugh Sanaee, Mohammad Reza Vakili, Amir Hasan Soleimani, Ommoleila Molavi, Chengsheng Wu, Raymond Lai, Igor M. Paiva, Yuen Morrissey
Publikováno v:
Cancers, Vol 11, Iss 2, p 248 (2019)
Cancers, vol 11, iss 2
Cancers
Volume 11
Issue 2
Cancers, vol 11, iss 2
Cancers
Volume 11
Issue 2
STAT3 is an oncoprotein which has been shown to contribute to drug resistance in multiple myeloma (MM). Nonetheless, the clinical utility of STAT3 inhibitors in treating MM has been limited, partly related to some of their pharmacologic properties. T
Autor:
Mohammad Reza Vakili, Theresa Donaldson, Tania Mysak, Afsaneh Lavasanifar, Laurine Sanderson, Forugh Sanaee
Publikováno v:
Journal of Pharmacy & Pharmaceutical Sciences, Vol 21, Iss 1s (2018)
PURPOSE: Alberta Health Services (AHS) recommends the adoption of a new neonatal multi-trace element formulation containing zinc sulfate, copper sulfate, selenious acid and sodium iodide to be compounded internally in appropriate AHS pharmacies. The
Publikováno v:
Biopharmaceutics & Drug Disposition. 34:312-320
Nebivolol is a third-generation β1-adrenoceptor blocker with β3 agonistic properties (AR). It has a low oral bioavailability that is speculated to be due to its hepatic first-pass metabolism. Inflammation is known to suppress the clearance of drugs
Publikováno v:
Biopharmaceuticsdrug disposition. 34(6)
Nebivolol is a third-generation β1-adrenoceptor blocker with β3 agonistic properties (AR). It has a low oral bioavailability that is speculated to be due to its hepatic first-pass metabolism. Inflammation is known to suppress the clearance of drugs